GlobeNewswire by notified

Anmodning om ophævelse af suspension af afdelinger i Investeringsforeningen Nordea Invest

Share

De tekniske problemer er nu løst og det er igen muligt at stille priser for nedenstående afdelinger, hvorfor handelen med nedenstående afdelinger genoptages.

Short nameNavnISIN
NDINSCKL1 Nordea Invest Nordic Small Cap KL 1 DK0015974695
NDIESCSKL1 Nordea Invest European Small Cap Stars KL 1 DK0015960983
NDIDKKL1 Nordea Invest Danmark KL 1 DK0010265859
NDIGSCKL1 Nordea Invest Global Small Cap KL 1 DK0016050974
NDIEUSTKL1 Nordea Invest European Stars KL 1 DK0010265693
NDINASTKL1 Nordea Invest North American Stars KL 1 DK0010265776
NDIGUAKL1 Nordea Invest Globale UdbytteAktier KL 1 DK0010265503
NDIGOBLKL1 Nordea Invest Globale obligationer KL 1 DK0010170398
NDIMLOKL1 Nordea Invest Mellemlange obligationer KL 1 DK0015168686
NDIAKTIIKL1 Nordea Invest Aktier II KL 1 DK0015357065
NDIEHYKL1 Nordea Invest European HYB KL 1 DK0016306798
NDIDAFKL1 Nordea Invest Danske aktier fokus KL 1 DK0060012466
NDIAKL1 Nordea Invest Aktier KL 1 DK0010250158
NDIVOBKL1 Nordea Invest Virksomhedsobligationer KL 1 DK0016015399
NDIVOHKL1 Nordea Invest Virksomhedsobli. Højrente KL1 DK0016067432
NDIHOJLKL1 Nordea Invest HøjrenteLande KL 1 DK0016254899
NDIGSTKL1 Nordea Invest Global Stars KL 1 DK0010301324
NDIEMKL1 Nordea Invest Emerging Markets KL 1 DK0010308170
NDIKOLKL1 Nordea Invest Korte obligationer Lagerbeskattet KL 1 DK0060014678
NDISTABKL1 Nordea Invest Stabil Balanceret KL 1 DK0060014595
NDISTABAKL1 Nordea Invest Stabile Aktier KL 1 DK0060048304
NDINOSKL1 Nordea Invest Nordic Stars KL 1 DK0060095735
NDISTAAKL1 Nordea Invest Stabile Aktier Akkumulerende KL 1 DK0060096030
NDI4KL1 Nordea Invest Basis 4 KL 1 DK0060075893
NDIB1KL1 Nordea Invest Basis 1 KL 1 DK0016195860
NDIB2KL1 Nordea Invest Basis 2 KL 1 DK0016195944
NDIB3KL1 Nordea Invest Basis 3 KL 1 DK0016196082
NDIKMKL1 Nordea Invest Klima og Miljø KL 1 DK0060192185
NDIGAIKL1 Nordea Invest Globale Aktier Indeks KL 1 DK0060451623
NDIESKL1 Nordea Invest Emerging Stars KL 1 DK0060586394
NDINAEKL1 Nordea Invest North America Enhanced KL 1 DK0060831451
NDIGLENHKL1 Nordea Invest Global Enhanced KL 1 DK0060949881
NDIEUENHKL1 Nordea Invest Europe Enhanced KL 1 DK0060949964
NDIJAPENHKL1 Nordea Invest Japan Enhanced KL 1 DK0060950038
NDIEMMAENKL1 Nordea Invest Emerging Markets Enhanced KL 1 DK0060950111
NDIGSEKL1 Nordea Invest Global Small Cap Enhanced KL 1 DK0061112893
NDIBAKL1 Nordea Invest Bæredygtige Aktier KL 1 DK0061116027
NDIBOKL1 Nordea Invest Bæredygtige Obligationer KL 1 DK0061139748
NDIFONKL1 Nordea Invest Fonde KL 1 DK0060145183
NDIKOKL1 Nordea Invest Korte obligationer KL 1 DK0060268506
NDIVOMKL1 Nordea Invest Verdens Obligationsmarkeder KL 1 DK0060353886
NDILAOKL1 Nordea Invest Lange Obligationer KL 1 DK0060187342

Med venlig hilsen
Nordea Invest


Tom Holflod
Senior Product Manager

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Vereniging Aegon to participate in current share buyback program8.12.2023 20:00:00 CET | Press release

The Hague, December 8, 2023 - Aegon has entered into an agreement with its largest shareholder, Vereniging Aegon, to partially participate in Aegon’s current EUR 1.5 billion share buyback program. The repurchase of shares from Vereniging Aegon will commence as soon as Aegon has repurchased shares for an amount of EUR 750 million under the buyback program and is expected to run until the end of the share buyback program. Barring unforeseen circumstances, the share buyback is expected to be completed on or before June 30, 2024. As of December 7, Aegon has repurchased 149.8 million shares representing EUR 703.9 million. Aegon began its EUR 1.5 billion share buyback program on July 6, 2023 following the completion of the transaction to combine Aegon’s Dutch pension, life and non-life insurance, banking, and mortgage origination activities with a.s.r., that was announced on July 4, 2023. Vereniging Aegon will participate pro-rata in the share buyback program based on its combined common sha

Clean Motion AB skriver under projektavtal med EU8.12.2023 19:09:01 CET | Pressemelding

Elfordonstillverkaren Clean Motion AB har skrivit under ett projektavtal inom EU Horizon Europe programmet. Projektet GIANTS (Green Intelligent Affordable Nano Transport Solutions) har totalt 23 projektpartners och en total budget på 15,1 miljoner Euro varav 12 miljoner Euro är bidrag från EU. Clean Motion har den tredje största budgeten och kommer att tilldelas ett bidrag från EU på 1,3 miljoner Euro fördelat över projektperioden på 42 månader, med start i januari 2024. Clean Motion AB, en ledare inom utvecklingen av hållbara transportlösningar, är stolta över att meddela sitt deltagande i GIANTS-projektet, finansierat av EU inom ramen för Horizon Europe-programmet. Projektets totala budget uppgår till 15,1 miljoner euro där EU står för 12 miljoner euro. Clean Motions totala budget i projektet är 1,9 miljoner euro med EU-finansiering om 1,3 miljoner euro. Inom projektet som löper från januari 2024 och 42 månader framåt kommer vi att samarbeta med 22 andra partners, bland andra Renault

Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:50:33 CET | Press release

PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions. New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software. CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial, and operational planning, including supply chain, workforce, and capital expenses. The solution, which supports customers across vertical industries, is particula

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment8.12.2023 17:50:00 CET | Press release

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation8.12.2023 17:45:00 CET | Press release

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs 7.3 months;